RefleXion Medical, a Hayward, CA-based medical equipment company developing biology-guided radiotherapy system for targeted, personalized cancer treatment, closed a $46m Series B round of funding.
The round was led by new investor KCK Group, a family investment fund, with participation from existing investors Pfizer Venture Investments, Venrock and Sofinnova Partners, RefleXion’s largest shareholder. In conjunction with the financing, Nael Kassar and Greg Garfield from KCK Group will join the RefleXion Board of Directors.
The company intends to use the proceeds to expanding its Engineering, Regulatory and Commercial organizations.
Led by Dr. Samuel Mazin, Co-Founder/President and inventor of core technology, RefleXion provides a biology-guided radiotherapy system (BgRT) that utilizes both anatomic (Computed Tomography) and functional (Positron Emission Tomography) imaging data to guide personalized radiotherapy. Delivering targeted treatment based on the patient’s individual biology, PET-CT guided radiotherapy has the potential to deliver a higher dose of therapeutic radiation to cancerous lesions while sparing surrounding healthy tissue.
In addition to improve treatment efficacy for primary lesions and track multiple tumors, the RefleXion biology-guided radiotherapy system may also enable several applications of precision medicine including the use of novel PET tracers to adapt treatment based on relevant biological tumor characteristics such as tumor hypoxia, cellular proliferation, DNA synthesis and genetic markers.